Cell Therapy Manufacturing Market (7th Edition): Trends and Forecast Till 2035 - Distribution by Type of Cell Therapy, Source of Cells, Scale of Operation, Type of Manufacturer, and Geography

As per Roots Analysis, the cell therapy manufacturing market is estimated to grow from USD 7,172 million in the current year to USD 14,017 million by 2035, at a CAGR of 7.7% during the forecast period, till 2035.

Cell Therapy Manufacturing Market: Growth and Trends

Over the years, numerous technological innovations and discoveries have transformed the field of medicine. One notable advancement is the emergence of cell-based therapies, which have shown substantial therapeutic promise and are largely free from many of the toxicity issues linked to traditional pharmacological treatments. Researchers are exploring over 1,000 cell and gene therapy candidates targeting a wide range of disease indications. Of these, approximately 45 cell-based therapies have already received approval from various global regulatory agencies. In addition, several organizations are implementing initiatives to tackle manufacturing challenges and ensure the ongoing success of these innovative therapies.

The manufacturing of cell and gene therapies is a complex process that occurs in a meticulously controlled, contamination-free environment and involves multiple critical stages, such as isolating, modifying, and expanding immune cells, including T-cells and stem cells. Each of these stages demand the use of specialized closed systems and rigorous compliance with regulatory standards to guarantee the safety and effectiveness of the final products. Companies are focused on enhancing cell handling and processing equipment, improving ancillary materials and cell counting techniques, and addressing current logistical challenges. Consequently, it is becoming increasingly essential for cell therapy developers to invest in flexible and automated technologies to mitigate the risks associated with human error during the production of these advanced therapeutic candidates. These improvements are expected to help companies maintain quality and consistency of products while keeping costs manageable.

Growth Drivers: Strategic Enablers of Market Expansion

The field of cell therapy is experiencing rapid growth, characterized by an increase in clinical trial and a rise in regulatory approvals. With a greater number of therapies advancing from initial research to late-stage clinical trials, patients have more opportunities to access these treatments. A report from the American Society of Gene & Cell Therapy (ASGCT) indicates that there are currently 4,418 active programs in the combined gene, cell, and RNA therapy pipeline, comprising 2,155 gene therapies and 966 non-genetically modified cell therapies, along with 79 new gene therapy trials (57% focused on oncology) and 27 new cell therapy trials (74% in non-oncology) that were initiated during that quarter. This progress will be bolstered by the establishment of local manufacturing facilities for cell therapies.

Market Challenges: Critical Barriers Impeding Progress

Despite strong demand, the cell therapy manufacturing sector faces multiple challenges in moving cell-based therapy products from the lab to clinical scale. These obstacles include a shortage of skilled workers, regulatory compliance issues, and insufficient advanced facilities and infrastructure. The manufacturing processes for cell therapy necessitate sterile, high-grade clean rooms and strict monitoring of containment levels to ensure product integrity and compliance. Due to these intricate procedures, scaling up cell therapy manufacturing can be considerably difficult.

Cell Therapy Manufacturing Market: Key Insights

The report delves into the current state of the cell therapy manufacturing market and identifies potential growth opportunities within industry. Some key findings from the report include:

Currently, close to 200 industry players are engaged in cell therapy manufacturing; of these, ~45% of players are headquartered in the US.

Cell Therapy Manufacturing Market - IMG1

More than 40% of industry players offer both T-cells and stem cells, as T-cells have a lower risk of rejection while stem cells possess a unique ability to regenerate or repair damaged cells and tissues.
More than 80 non-industry players are currently engaged in the manufacturing of cell therapies; around 55% of these players are based in the US.
~30% of the non-industry cell therapy manufacturers were established before 2001; among these, more than 60% of players utilize both autologous and allogeneic source of cells.
Several clinical trials evaluating immune cell therapies have been registered till date; majority (65%) of these studies have been conducted across various trial sites in Asia-Pacific.
The rising interest in this market is reflected from the diverse partnerships established among various stakeholders in the recent past; in fact, >55% of the deals have been inked post 2022.

Cell Therapy Manufacturing Market - IMG2

70% of the industry players have expanded their existing capacities and capabilities through establishment of new facilities; more than 40% facilities are dedicated to manufacturing of T cells.
Over 55% of major big pharma initiatives in this domain have been pursued through partnerships and collaborations; of these, a sizeable proportion of the initiatives were undertaken by Bristol-Myers Squibb.
~95% of the current installed cell therapy manufacturing capacity (in terms of number of cleanrooms) is presently available with industry players; maximum capacity is installed in facilities based in North America.
The rising demand for cell-based therapies stems from increasing product approvals, advancing therapies, expanding healthcare infrastructure, and growing patient awareness.
The cell therapy manufacturing domain is poised to grow at a CAGR of 8.25%, owing to high capital costs and advanced technologies; ~60% of manufacturing activities are expected to be outsourced to CMOs.

Owing to the rising prevalence of cancer, and shift in patient preferences towards tailored cell therapies and advancements in cell therapy manufacturing technologies, the market is poised for a steady growth in the future.
North America is expected to capture a significant share of the cell therapy manufacturing market in the current year owing to rapid innovation of technologies within the region.
Driven by the success of approved cell therapies developed by prominent players in the US, the commercial cell therapy manufacturing market is expected to grow at CAGR of 12.93%.
Given the rapid clinical success and rising demand for cell therapies, coupled with their extensive potential in treating disorders like blood cancer, the industry is well-positioned for future growth.

Cell Therapy Manufacturing Market

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of Cell Therapy

CAR-T Cell Therapy
Stem Cell Therapy
TCR Therapy
TIL Therapy
Dendritic Cell Therapy
Others

By Source of Cells

Autologous Cells
Allogeneic Cells
Unspecified Cells

By Scale of Operation

Clinical Scale
Commercial Scale

By Type of Manufacturer

In-house Manufacturers
Contract Manufacturing Organizations

By Geographical Regions

North America
US
Canada
Europe
France
Germany
Italy
Spain
UK
Rest of Europe

Asia-Pacific and Rest of the World

Argentina
Australia
Brazil
China
India
Israel
Japan
Singapore
South Africa
South Korea
Taiwan

Cell Therapy Manufacturing Market: Key Segments

CAR-T Cell Therapies Accounts for the Largest Share in the Cell Therapy Manufacturing Market

In the present year, the CAR-T cell therapies segment holds the largest market share (approximately 65%), attributed to the shorter treatment regimen that requires fewer infusions. Further, the segment of other cell therapies, which includes natural killer cell therapies and gene-modified cell therapies, is anticipated to experience a higher compound annual growth rate (CAGR) of 16.15% throughout the forecast period. The favorable safety profile of NK cells reduces the risk of conditions such as graft-versus-host disease. Additionally, their potential to function as off-the-shelf therapies propels this growth.

Autologous Cells Hold the Highest Share in the Cell Therapy Manufacturing Market

In 2035, the autologous segment is projected to hold a larger share of the cell therapy manufacturing market, accounting for over 50%. Additionally, this segment is expected to experience a notable growth rate throughout the forecast period. This can be attributed mainly to the focus of autologous cell therapy manufacturing on the patient's own cells, which minimizes the risk of immune rejection that can result in severe complications such as graft-versus-host disease.

North America Dominates the Market by Securing Highest Share

Based on our market forecast, North America is expected to hold the largest share of the cell therapy manufacturing market, accounting for approximately 45% by 2025. Further, we anticipate that North America will experience a comparatively faster growth rate of 9.70% until 2035. It is important to highlight that around 60% of this market derives from clinical cell therapy manufacturing. In the clinical cell therapy manufacturing sector, the U.S. has become a central hub for manufacturers, bolstered by their innovation-friendly regulatory framework and highly qualified workforce. This regional concentration enables efficient scaling of cell therapy production, from initial development stages to commercial supply.

Primary Research Overview

The opinions and insights presented in the market report were also influenced by discussions held with senior stakeholders in the industry. The market report includes detailed transcripts of interviews conducted with the following individuals:

Marketing Manager, Cell Therapy, Mid-sized Company, Australia
Director, UK
Marketing Director, Small Company, Belgium
Management Board Vice-President, Large Company, Poland
Senior Director of Sales Advanced Therapies; Vice President of Marketing, Small Company, US
Business Administration Department Manager, Mid-sized Company, Japan
Chief Business Officer, Small Company, Netherlands
Director of Finance and Facility Operations, US
Senior Director, Very Large Company, Japan
Chief Executive Officer, Mid-sized Company, UK
Former Chief Technical Officer, Large Company, US
Former Chief Executive Officer, Small Company, Netherlands
Former General Manager, Small Company, France
Chief Executive Officer, Large Company, China
Executive Vice President Research and Development, Small Company, Israel
Former Business Development Manager, Mid-sized Company, UK
Professor and American Red Cross Chair in Transfusion Medicine, US
Former Co-Founder and Chief Executive Officer, Small Company, Singapore
Former Manager, Business Development and Operations-cGMP Manufacturing Unit, Mid-sized Company, Canada
Manager of Business Development, Small Company, US
Former Department Leader, Cell Therapy Innovation and Development, Mid-sized Company, France
Former Chief Executive Officer, Mid-sized Company, Australia
Chief Executive Officer, Small Company, Netherlands

Example Players in Cell Therapy Manufacturing Market

Advanced Therapies
AGC Biologics
Astellas Pharma
Catalent
Charles River Laboratories
City of Hope
Clinical Cell and Vaccine Production Facility (CVPF)
Evotec
Fraunhofer Institute for Cell Therapy and Immunology
ImmunityBio
Lonza
Merck Millipore
Miltenyi Biotec
Minaris Advanced Therapies
Newcastle Advanced Therapies
NHS Blood and Transplant
OBiO Tech
Pharmaron
Rayne Cell Therapy Suite
Resilience
Sartorius
Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility
SK pharmteco (Subsidiary of SK Inc.)
Takara Bio
Thermo Fisher Scientific

Cell Therapy Manufacturing Market: Research Coverage

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the cell therapy manufacturing market, focusing on key market segments, including [A] type of cell therapy, [B] source of cells, [C] scale of operation, [D] type of manufacturer, and [E] geographical regions.
Industry Players - Market Landscape 1: A detailed overview of the current market landscape of companies engaged of industry players in cell therapy manufacturing domain, featuring information on, along with information on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] location of manufacturing facility, [E] type of immune cell offered, [F] source of cells, [G] scale of operation, and [H] type of additional service offered.
Non-industry Players - Market Landscape 2: A detailed overview of the current market landscape of non-industry players in cell therapy manufacturing domain along with information on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] location of manufacturing facility, [E] type of immune cell offered, [F] source of cells, [G] scale of operation, and [H] type of additional service offered.
Regulatory Landscape: An overview of cell therapy manufacturing related regulations across various geographies, including North America (focusing on the US), Europe and Asia (focusing on Japan and China), featuring an analysis of the diverse certifications / accreditations awarded to the manufacturing facilities by important regulatory bodies across the globe.
Case Study 1: An overview of the various roadmaps published by different agencies across the globe in order to provide strategies to advance cell therapy manufacturing process.
Case Study 2: A detailed role of technology automation in cell therapy manufacturing in order to optimize the current manufacturing practices with the use of closed and single use systems. Further, it features a roadmap that provides information on the steps to develop automation devices, supported by two case studies
Company Profiles: In-depth profiles of prominent industry and non-industry players in North America, Europe and Asia-Pacific that are involved in cell therapy manufacturing based on [A] year of establishment, [B] location of headquarters, [C] product portfolio, [D] recent developments and [E] an informed future outlook.
Clinical Trial Analysis: An analysis of completed, ongoing and planned clinical trial, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, patient gender, study design, type of allocation, intervention model, type of masking, type of sponsor / collaborator most active players (in terms of number of clinical trial conducted) and geographical distribution of trials.
Partnerships and Collaborations: An in-depth analysis of the partnerships and collaborations that have been inked by cell therapy manufacturers, based on several relevant parameters, such as year of partnership, type of partnership, type of immune cell offered, scale of operation and most active players (in terms of number of partnerships). The chapter also highlights the regional distribution of partnership activity in this market.
Recent Expansions: A detailed analysis of expansions reported in the domain, along with analysis on several relevant parameters, such as [A] year of expansion, [B] status of expansion, [C] type of expansion, [D] location of facility, [E] amount invested, [F] type of immune cell offered, [G] type of service offered and [H] most active players.
Big Pharma Initiatives: An in-depth analysis of the various cell therapy manufacturing focused initiatives undertaken by big pharma players, based on several relevant parameters, such as [A] year of initiative, [B] type of initiative, [C] number of initiatives, [D] type of partnership, [E] number of partnerships, [F] type of facility expansion, [G] number of facility expansions, [H] region of facility expansion, [I] number of mergers and acquisitions, [J] number of funding and investment, [K] type of immune cell offered, and [L]scale of operation.
Capacity Analysis: An estimate an estimate of the overall installed capacity for the manufacturing of cell-based therapies, based on information reported by various industry stakeholders in the public domain, highlighting the distribution of the available capacity in terms of cleanroom area and number of cleanrooms.
Demand Analysis: An informed estimate of the annual commercial and clinical demand for cell therapies, across several relevant parameters, such as [A] type of cell therapy, and [B] key geographical regions.
Cost Price Analysis: A detailed analysis of various factors that are likely to influence the price of cell-based therapies, featuring different models / approaches adopted by manufacturers in order to determine the price of their proprietary offerings.
Make Versus Buy Decision Making Framework: A qualitative analysis that highlights the various factors that need to be taken into consideration by cell therapy developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
Total Cost of Ownership: A detailed total cost of ownership analysis based on company size, for cell therapy manufacturing organizations, over a period of 20 years.
SWOT Analysis: a discussion on strength, weaknesses, opportunities and threats, highlighting the relative effect of each SWOT parameter on the overall market dynamics.

Key Questions Answered in this Report

Which are the leading companies in cell therapy manufacturing market?
Which region dominates the cell therapy contract manufacturing market?
What are the key trends observed in the cell therapy manufacturing market?
What factors are likely to influence the evolution of this market?
What are the primary challenges faced by cell therapy contract manufacturers?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

Complementary PPT Insights Pack
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

Product Code: RA100392

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
- 2.2.1. Market Landscape and Market Trends
- 2.2.2. Market Forecast and Opportunity Analysis
- 2.2.3. Comparative Analysis
2.3. Database Building
- 2.3.1. Data Collection
- 2.3.2. Data Validation
- 2.3.3. Data Analysis
2.4. Project Methodology
- 2.4.1. Secondary Research
  - 2.4.1.1. Annual Reports
  - 2.4.1.2. Academic Research Papers
  - 2.4.1.3. Company Websites
  - 2.4.1.4. Investor Presentations
  - 2.4.1.5. Regulatory Filings
  - 2.4.1.6. White Papers
  - 2.4.1.7. Industry Publications
  - 2.4.1.8. Conferences and Seminars
  - 2.4.1.9. Government Portals
  - 2.4.1.10. Media and Press Releases
  - 2.4.1.11. Newsletters
  - 2.4.1.12. Industry Databases
  - 2.4.1.13. Roots Proprietary Databases
  - 2.4.1.14. Paid Databases and Sources
  - 2.4.1.15. Social Media Portals
  - 2.4.1.16. Other Secondary Sources
- 2.4.2. Primary Research
  - 2.4.2.1. Types of Primary Research
    - 2.4.2.1.1. Qualitative Research
    - 2.4.2.1.2. Quantitative Research
    - 2.4.2.1.3. Hybrid Approach
  - 2.4.2.2. Advantages of Primary Research
  - 2.4.2.3. Techniques for Primary Research
    - 2.4.2.3.1. Interviews
    - 2.4.2.3.2. Surveys
    - 2.4.2.3.3. Focus Groups
    - 2.4.2.3.4. Observational Research
    - 2.4.2.3.5. Social Media Interactions
  - 2.4.2.4. Key Opinion Leaders Considered in Primary Research
    - 2.4.2.4.1. Company Executives (CXOs)
    - 2.4.2.4.2. Board of Directors
    - 2.4.2.4.3. Company Presidents and Vice Presidents
    - 2.4.2.4.4. Research and Development Heads
    - 2.4.2.4.5. Technical Experts
    - 2.4.2.4.6. Subject Matter Experts
    - 2.4.2.4.7. Scientists
    - 2.4.2.4.8. Doctors and Other Healthcare Providers
  - 2.4.2.5. Ethics and Integrity
    - 2.4.2.5.1. Research Ethics
    - 2.4.2.5.2. Data Integrity
- 2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS

3.1. Chapter Overview
3.2. Forecast Methodology
- 3.2.1. Top-down Approach
- 3.2.2. Bottom-up Approach
- 3.2.3. Hybrid Approach
3.3. Market Assessment Framework
- 3.3.1. Total Addressable Market (TAM)
- 3.3.2. Serviceable Addressable Market (SAM)
- 3.3.3. Serviceable Obtainable Market (SOM)
- 3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
- 3.4.1. Qualitative Forecasting
- 3.4.2. Correlation
- 3.4.3. Regression
- 3.4.4. Extrapolation
- 3.4.5. Convergence
- 3.4.6. Sensitivity Analysis
- 3.4.7. Scenario Planning
- 3.4.8. Data Visualization
- 3.4.9. Time Series Analysis
- 3.4.10. Forecast Error Analysis
3.5. Key Considerations
- 3.5.1. Demographics
- 3.5.2. Government Regulations
- 3.5.3. Reimbursement Scenarios
- 3.5.4. Market Access
- 3.5.5. Supply Chain
- 3.5.6. Industry Consolidation
- 3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
- 4.2.1. Time Period
  - 4.2.1.1. Historical Trends
  - 4.2.1.2. Current and Forecasted Estimates
- 4.2.2. Currency Coverage
  - 4.2.2.1. Major Currencies Affecting the Market
  - 4.2.2.2. Factors Affecting Currency Fluctuations
  - 4.2.2.3. Impact of Currency Fluctuations on the Industry
- 4.2.3. Foreign Currency Exchange Rate
  - 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
  - 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 4.2.4. Recession
  - 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
  - 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
- 4.2.5. Inflation
  - 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 4.2.5.2. Potential Impact of Inflation on the Market Evolution
- 4.2.6. Interest Rates
  - 4.2.6.1. Interest Rates and Their Impact on the Market
  - 4.2.6.2. Strategies for Managing Interest Rate Risk
- 4.2.7. Commodity Flow Analysis
  - 4.2.7.1. Type of Commodity
  - 4.2.7.2. Origins and Destinations
  - 4.2.7.3. Values and Weights
  - 4.2.7.4. Modes of Transportation
- 4.2.8. Global Trade Dynamics
  - 4.2.8.1. Import Scenario
  - 4.2.8.2. Export Scenario
  - 4.2.8.3. Trade Policies
  - 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
  - 4.2.8.5. Impact of Trade Barriers on the Market
- 4.2.9. War Impact Analysis
  - 4.2.9.1. Russian-Ukraine War
  - 4.2.9.2. Israel-Hamas War
- 4.2.10. COVID Impact / Related Factors
  - 4.2.10.1. Global Economic Impact
  - 4.2.10.2. Industry-specific Impact
  - 4.2.10.3. Government Response and Stimulus Measures
  - 4.2.10.4. Future Outlook and Adaptation Strategies
- 4.2.11. Other Indicators
  - 4.2.11.1. Fiscal Policy
  - 4.2.11.2. Consumer Spending
  - 4.2.11.3. Gross Domestic Product
  - 4.2.11.4. Employment
  - 4.2.11.5. Taxes
  - 4.2.11.6. Stock Market Performance
  - 4.2.11.7. Cross Border Dynamics
4.3. Conclusion

5. EXECUTIVE SUMMARY

5.1. Executive Summary: Market Landscape
5.2. Executive Summary: Market Trends
5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

6.1. Chapter Overview
6.2. Introduction to Cell-based Therapies
- 6.2.1. Comparison of Cell-based Therapies and Other Biotechnology Products
- 6.2.2. Classification of Advanced Therapy Medicinal Products (ATMPs)
- 6.2.3. Current Market Landscape of ATMPs
6.3. Overview of Cell Therapy Manufacturing
6.4. Cell Therapy Manufacturing Models
- 6.4.1. Centralized Manufacturing
- 6.4.2. Decentralized Manufacturing
6.5. Scalability of Cell Therapy Manufacturing Processes
- 6.5.1. Scale-up
- 6.5.2. Scale-out
6.6. Types of Cell Therapy Manufacturers
6.7. Key Challenges for Manufacturing Cell Therapies
6.8. Key Factors Influencing Cell Therapy Manufacturing
- 6.8.1. Cell Characterization
- 6.8.2. Cost of Goods
6.9. Automation of Cell Therapy Manufacturing
6.10. Cell Therapy Manufacturing Supply Chain
6.11. Future Perspectives

7. CELL THERAPY MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE

7.1. Chapter Overview
7.2. Industry Players: Overall Market Landscape
- 7.2.1. Analysis by Year of Establishment
- 7.2.2. Analysis by Company Size
- 7.2.3. Analysis by Location of Headquarters (Region)
- 7.2.4. Analysis by Location of Headquarters (Country)
- 7.2.5. Analysis by Company Size and Location of Headquarters (Region)
- 7.2.6. Analysis by Location of Manufacturing Facility
- 7.2.7. Analysis by Type of Immune Cell Offered
- 7.2.8. Analysis by Source of Cells
- 7.2.9. Analysis by Scale of Operation
- 7.2.10. Analysis by Type of Additional Service Offered

8. CELL THERAPY MANUFACTURERS (NON-INDUSTRY PLAYERS): MARKET LANDSCAPE

8.1. Chapter Overview
8.2. Non-Industry Players: Overall Market Landscape
- 8.2.1. Analysis by Year of Establishment
- 8.2.2. Analysis by Location of Headquarters (Region)
- 8.2.3. Analysis by Location of Headquarters (Country)
- 8.2.4. Analysis by Location of Manufacturing Facility
- 8.2.5. Analysis by Type of Immune Cell Offered
- 8.2.6. Analysis by Source of Cell
- 8.2.7. Analysis by Scale of Operation
- 8.2.8. Analysis by Type of Additional Service Offered

9. REGULATORY LANDSCAPE

9.1. Chapter Overview
9.2. Current Scenario
- 9.2.1. Regulatory Guidelines in North America
- 9.2.2. Regulatory Guidelines in Europe
- 9.2.3. Regulatory Guidelines in Asia-Pacific
  - 9.2.3.1. Regulatory Guidelines in Japan
  - 9.2.3.2. Regulatory Guidelines in China
- 9.2.4. Conditional Approvals
9.3. Regulatory Authorities for Cell Therapy Manufacturing
- 9.3.1. Cell Therapy Manufacturing (Industry Players): Regulatory Authorities
9.4. Summary of Guidelines for Early-Stage Manufacturing of Cell Therapies
9.5. Existing Challenges to Early-Stage Manufacturing of Cell Therapies
9.6. Variability in Regulatory Guidelines across Different Geographies

10. CASE STUDY: ROADMAPS FOR OVERCOMING CHALLENGES RELATED TO CELL THERAPY MANUFACTURING

10.1. Chapter Overview
10.2. Roadmap for the US
- 10.2.1. Cell Processing
- 10.2.2. Cell Preservation, Distribution and Handling
- 10.2.3. Process Automation and Data Analytics
- 10.2.4. Process Monitoring and Quality Control
- 10.2.5. Standardization and Regulatory Support
- 10.2.6. Workforce Development
- 10.2.7. Supply Chain and Logistics
10.3. Roadmaps for Other Geographies
- 10.3.1. Europe
- 10.3.2. Asia-Pacific

11. CASE STUDY: AUTOMATION TECHNOLOGIES FOR CELL THERAPY MANUFACTURING

11.1. Chapter Overview
11.2. Automation of Cell Therapy Manufacturing Processes
- 11.2.1. Closed Systems
- 11.2.2. Single-use Systems
- 11.2.3. Modular Systems
11.3. Growth Drivers and Roadblocks
11.4. Case Studies
- 11.4.1. Roadmap to Develop an Automated Cell Manufacturing / Processing Device
- 11.4.2. Automating the Cell Therapy Manufacturing Process
- 11.4.3. Advancement to Automation of Cell Therapy Manufacturing Process
- 11.4.4. GMP-in-a-Box
- 11.4.5. List of Automated and Closed Cell Therapy Processing Systems

12. COMPANY PROFILES: INDUSTRY PLAYERS

12.1. Chapter Overview
12.2. Service Providers in North America
- 12.2.1. Advanced Therapies
  - 12.2.1.1. Company Overview
  - 12.2.1.2. Financial Information
  - 12.2.1.3. Service Portfolio
  - 12.2.1.4. Manufacturing Facilities and Capabilities
  - 12.2.1.5. Recent Developments and Future Outlook
similar details are presented for other below mentioned players based on information in the public domain
- 12.2.2. AGC Biologics
- 12.2.3. Catalent
- 12.2.4. Charles River Laboratories
- 12.2.5. ImmunityBio
- 12.2.6. Merck Millipore
- 12.2.7. Minaris Advanced Therapies
- 12.2.8. Resilience
- 12.2.9. SK pharmteco (Subsidiary of SK Inc.)
- 12.2.10. Thermo Fisher Scientific
12.3. Service Providers in Europe
- 12.3.1. Evotec
- 12.3.2. Lonza
- 12.3.3. Miltenyi Biotec
- 12.3.4. Sartorius
12.4. Service Providers in Asia-Pacific
- 12.4.1. Astellas Pharma
- 12.4.2. OBiO Tech
- 12.4.3. Pharmaron
- 12.4.4. Takara Bio

13. COMPANY PROFILES: NON-INDUSTRY PLAYERS

13.1. Chapter Overview
13.2. City of Hope
- 13.2.1. Overview
- 13.2.2. Service Portfolio
- 13.2.3. Type of Additional Service Offered
similar details are presented for other below mentioned players based on information in the public domain
13.3. Clinical Cell and Vaccine Production Facility (CVPF)
13.4. Fraunhofer Institute for Cell Therapy and Immunology
13.5. Newcastle Advanced Therapies
13.6. NHS Blood and Transplant
13.7. Rayne Cell Therapy Suite (King's College London)
13.8. Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility

14. NON-PROFIT ORGANIZATIONS IN CELL THERAPY MANUFACTURING

14.1. Chapter Overview
14.2. Cell Therapy Manufacturing: Non-Profit Organizations
- 14.2.1. CellCAN
- 14.2.2. Cell Therapy Manufacturing Cooperative Research Center
- 14.2.3. National Cell Manufacturing Consortium (NCMC)
- 14.2.4. California Institute of Regenerative Medicine (CIRM)
14.3. Cell Therapy Manufacturing: International Societies

15. CLINICAL TRIAL ANALYSIS

15.1. Chapter Overview
15.2. Scope and Methodology
15.3. Cell Therapies: Clinical Trial Analysis
- 15.3.1. Analysis by Trial Registration Year
- 15.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
- 15.3.3. Analysis by Trial Status
- 15.3.4. Analysis by Trial Registration Year and Trial Status
- 15.3.5. Analysis by Trial Phase
- 15.3.6. Analysis of Enrolled Patient Population by Trial Phase
- 15.3.7. Analysis by Patient Gender
- 15.3.8. Analysis by Study Design
  - 15.3.8.1. Analysis by Type of Allocation
  - 15.3.8.2. Analysis by Intervention Model
  - 15.3.8.3. Analysis by Type of Masking
- 15.3.9. Analysis by Type of Sponsor / Collaborator
- 15.3.10. Most Active Players: Analysis by Number of Registered Trials
- 15.3.11. Analysis by Geography
  - 15.3.11.1. Analysis of Clinical Trials by Geography
  - 15.3.11.2. Analysis of Clinical Trials by Trial Status and Geography
  - 15.3.11.3. Analysis of Enrolled Patient Population by Trial Status and Geography

16. PARTNERSHIPS AND COLLABORATIONS

16.1. Chapter Overview
16.2. Partnership Models
16.3. Cell Therapy Manufacturing: List of Partnerships
- 16.3.1. Analysis by Year of Partnership
- 16.3.2. Analysis by Type of Partnership
- 16.3.3. Analysis by Year and Type of Partnership
16.4. Analysis by Type of Immune Cell Offered
16.5. Analysis by Scale of Operation
16.6. Most Active Players: Analysis by Number of Partnerships
16.7. Analysis by Geography
- 16.7.1. Local and International Agreements
- 16.7.2. Intracontinental and Intercontinental Agreements

17. RECENT EXPANSIONS

17.1. Chapter Overview
17.2. Type of Expansions
17.3. Cell Therapy Manufacturing: Recent Expansions
- 17.3.1. Analysis by Year of Expansion
- 17.3.2. Analysis by Type of Expansion
- 17.3.3. Analysis by Year and Type of Expansion
- 17.3.4. Analysis by Location of Expanded Facility (Region)
- 17.3.5. Analysis by Location of Expanded Facility (Country)
- 17.3.6. Analysis by Type of Expansion and Location of Headquarters (Country)
- 17.3.7. Analysis by Type of Immune Cell Offered
- 17.3.8. Analysis by Type of Expansion and Type of Immune Cell Offered
- 17.3.9. Analysis by Scale of Operation
- 17.3.10. Most Active Players: Analysis by Number of Expansions
- 17.3.11. Most Active Players: Analysis by Area of Expansion

18. BIG PHARMA INITIATIVES

18.1. Chapter Overview
18.2. Cell Therapy Manufacturing: List of Big Pharma Players
18.3. Cell Therapy Manufacturing: List of Initiatives by Big Pharma Players
- 18.3.1. Analysis by Year of Initiative
- 18.3.2. Analysis by Type of Initiative
- 18.3.3. Analysis by Year and Type of Initiative
- 18.3.4. Big Players: Analysis by Number of Initiatives
- 18.3.5. Analysis by Type of Partnership
- 18.3.6. Big Players: Analysis by Number of Partnerships
- 18.3.7. Analysis by Type of Facility Expansion
- 18.3.8. Big Players: Analysis by Number of Facility Expansions
- 18.3.9. Big Players: Analysis by Region of Facility Expansion
- 18.3.10. Big Players: Analysis by Number of Mergers and Acquisitions
- 18.3.11. Big Players: Analysis by Number of Funding and Investment
- 18.3.12. Analysis by Type of Immune Cell Offered
- 18.3.13. Analysis by Scale of Operation
- 18.3.14. Analysis of Big Pharma Players by Scale of Operation
- 18.3.15. Big Pharma Initiatives Summary

19. CAPACITY ANALYSIS

19.1. Chapter Overview
19.2. Industry Players: Key Assumptions and Methodology
- 19.2.1. Cell Therapy Manufacturing: Global Installed Capacity (Number of Cleanrooms)
  - 19.2.1.1. Analysis by Company Size
  - 19.2.1.2. Analysis by Scale of Operation
  - 19.2.1.3. Analysis by Location of Manufacturing Facility
  - 19.2.1.4. Analysis by Company Size and Location of Manufacturing Facility
  - 19.2.1.5. Analysis by Scale of Operation and Location of Manufacturing Facility
- 19.2.2. Cell Therapy Manufacturing: Global Installed Capacity (Cleanroom Area)
  - 19.2.2.1. Analysis by Company Size
  - 19.2.2.2. Analysis by Scale of Operation
  - 19.2.2.3. Analysis by Location of Manufacturing Facility
  - 19.2.2.4. Analysis by Company Size and Location of Manufacturing Facility
  - 19.2.2.5. Analysis by Scale of Operation and Location of Manufacturing Facility
19.3. Non- Industry Players: Key Assumptions and Methodology
- 19.3.1. Cell Therapy Manufacturing: Global Installed Capacity (Number of Cleanrooms)
  - 19.3.1.1. Analysis by Scale of Operation
  - 19.3.1.2. Analysis by Location of Manufacturing Facility
- 19.3.2. Cell Therapy Manufacturing: Global Installed Capacity (Cleanroom Area)
  - 19.3.2.1. Analysis by Scale of Operation
  - 19.3.2.2. Analysis by Location of Manufacturing Facility
19.4. Concluding Remarks

20. DEMAND ANALYSIS

20.1. Chapter Overview
20.2. Assumptions and Methodology
20.3. Global Demand for Cell Therapy Manufacturing
20.4. Global Clinical Demand for Cell Therapy Manufacturing
- 20.4.1. Clinical Demand: Analysis by Type of Cell Therapy
- 20.4.2. Clinical Demand: Analysis by Geography
20.5. Global Commercial Demand for Cell Therapy Manufacturing
- 20.5.1. Commercial Demand: Analysis by Type of Cell Therapy
- 20.5.2. Commercial Demand: Analysis by Geography

21. COST PRICE ANALYSIS

21.1. Chapter Overview
21.2. Factors Contributing to the High Price of Cell Therapies
21.3. Pricing Models for Cell Therapies
- 21.3.1. Based on Associated Costs for T-cell Therapies
- 21.3.2. Based on Associated Costs for Stem Cell Therapies
- 21.3.3. Based on Availability of Competing Products
- 21.3.4. Based on Target Patient Segment
- 21.3.5. Based on the Opinions of Industry Experts
21.4. Cell Therapy Cost Optimization
- 21.4.1. Role of Cost of Goods Sold
- 21.4.2. Role of Automation
21.5. Role of Cell Therapy Contract Manufacturing Organizations
21.6. Reimbursement-related Considerations for Cell Therapies
- 21.6.1. Case Study: The National Institute for Health and Care Excellence's (NICE) Appraisal of CAR-T Therapies

22. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

22.1. Chapter Overview
22.2. Assumptions and Key Parameters
22.3. Cell Therapy Manufacturing: Make versus Buy Decision Making
- 22.3.1. Scenario 1
- 22.3.2. Scenario 2
- 22.3.3. Scenario 3
- 22.3.4. Scenario 4

23. TOTAL COST OF OWNERSHIP FOR CELL THERAPY MANUFACTURING ORGANIZATIONS

23.1. Chapter Overview
23.2. Key Parameters
23.3. Assumptions and Methodology
23.4. Sample Dataset for the Estimation of Total Cost of Ownership
23.5. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20
23.6. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by CAPEX and OPEX, Y0 and Y20
- 23.6.1. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by CAPEX, Y0
- 23.6.2. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by OPEX, Y1-Y20

24. SWOT ANALYSIS

24.1. Chapter Overview
24.2. Strengths
24.3. Weaknesses
24.4. Opportunities
24.5. Threats
24.6. Comparison of SWOT Factors

25. SURVEY ANALYSIS

25.1. Chapter Overview
25.2. Analysis by Designation of Respondents
25.3. Analysis by Type of Cell Therapy
25.4. Analysis by Scale of Operation
25.5. Analysis by Source of Cells
25.6. Analysis by Type of Cell Culture System Used
25.7. Analysis by Availability of Fill / Finish Services

26. GLOBAL CELL THERAPY MANUFACTURING MARKET

26.1. Chapter Overview
26.2. Assumptions and Methodology
26.3. Global Cell Therapy Manufacturing Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
26.4. Roots Analysis Perspective on Market Growth
26.5. Scenario Analysis
- 26.5.1. Conservative Scenario
- 26.5.2. Optimistic Scenario
26.6. Key Market Segmentations

27. CELL THERAPY MANUFACTURING MARKET, BY TYPE OF CELL THERAPY

27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy
- 27.3.1. Cell Therapy Manufacturing Market for CAR-T Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 27.3.2. Cell Therapy Manufacturing Market for Stem Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 27.3.3. Cell Therapy Manufacturing Market for TCR Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 27.3.4. Cell Therapy Manufacturing Market for TIL Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 27.3.5. Cell Therapy Manufacturing Market for Dendritic Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 27.3.6. Cell Therapy Manufacturing Market for Other Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
27.4. Data Triangulation and Validation

28. CELL THERAPY MANUFACTURING MARKET, BY SOURCE OF CELLS

28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Cell Therapy Manufacturing Market: Distribution by Source of Cells
- 28.3.1. Cell Therapy Manufacturing Market for Autologous Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 28.3.2. Cell Therapy Manufacturing Market for Allogeneic Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 28.3.3. Cell Therapy Manufacturing Market for Other Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
28.4. Data Triangulation and Validation

29. CELL THERAPY MANUFACTURING MARKET, BY SCALE OF OPERATION

29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Cell Therapy Manufacturing Market: Distribution by Scale of Operation
- 29.3.1. Cell Therapy Manufacturing Market for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 29.3.2. Cell Therapy Manufacturing Market for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)

30. CELL THERAPY MANUFACTURING MARKET, BY TYPE OF MANUFACTURER

30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Cell Therapy Manufacturing Market: Distribution by Type of Manufacturer
- 30.3.1. Cell Therapy Manufacturing Market for Contract Manufacturing Organizations, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 30.3.2. Cell Therapy Manufacturing Market for In-House Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
30.4. Data Triangulation and Validation

31. CELL THERAPY MANUFACTURING MARKET, BY GEOGRAPHY

31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. Cell Therapy Manufacturing Market: Distribution by Geography
- 31.3.1. Clinical Cell Therapy Manufacturing Market
  - 31.3.1.1. Clinical Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.1.1.1. Clinical Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.1.1.2. Clinical Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  - 31.3.1.2. Clinical Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.1.2.1. Clinical Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.1.2.2. Clinical Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.1.2.3. Clinical Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.1.2.4. Clinical Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.1.2.5. Clinical Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  - 31.3.1.3. Clinical Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.1.3.1. Clinical Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.1.3.2. Clinical Cell Therapy Manufacturing Market in Singapore, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.1.3.3. Clinical Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.1.3.4. Clinical Cell Therapy Manufacturing Market in Israel, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.1.3.5. Clinical Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.1.3.6. Clinical Cell Therapy Manufacturing Market in Taiwan, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.1.3.7. Clinical Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.1.3.8. Clinical Cell Therapy Manufacturing Market in Argentina, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.1.3.9. Clinical Cell Therapy Manufacturing Market in South Africa, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 31.3.2. Commercial Cell Therapy Manufacturing Market
  - 31.3.2.1. Commercial Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.2.1.1. Commercial Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.2.1.2. Commercial Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  - 31.3.2.2. Commercial Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.2.2.1. Commercial Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.2.2.2. Commercial Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.2.2.3. Commercial Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.2.2.4. Commercial Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.2.2.5. Commercial Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.2.2.6. Commercial Cell Therapy Manufacturing Market in Rest of Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  - 31.3.2.3. Commercial Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.2.3.1. Commercial Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.2.3.2. Commercial Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.2.3.3. Commercial Cell Therapy Manufacturing Market in Australia, Historical Trends (since 2023) and Forecasted Estimates (2025-2035)
    - 31.3.2.3.4. Commercial Cell Therapy Manufacturing Market in India, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.2.3.5. Commercial Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 31.3.2.3.6. Commercial Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2024) and Forecasted Estimates (till 2035)
31.4. Penetration Growth (P-G) Matrix
31.5. Market Dynamics Assessment

32. CELL THERAPY MANUFACTURING MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

32.1. Cell Therapy Manufacturing Market in North America: Distribution by Type of Cell therapy
- 32.1.1. Cell Therapy Manufacturing Market in North America for CAR-T Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.1.2. Cell Therapy Manufacturing Market in North America for Stem Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.1.3. Cell Therapy Manufacturing Market in North America for TCR Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.1.4. Cell Therapy Manufacturing Market in North America for TIL Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.1.5. Cell Therapy Manufacturing Market in North America for Dendritic Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.1.6. Cell Therapy Manufacturing Market in North America for Other Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.2. Cell Therapy Manufacturing Market in North America: Distribution by Source of Cells
- 32.2.1. Cell Therapy Manufacturing Market in North America for Autologous Cells, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.2.2. Cell Therapy Manufacturing Market in North America for Allogeneic Cells, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.2.3. Cell Therapy Manufacturing Market in North America for Other Cells, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.3. Cell Therapy Manufacturing Market in North America: Distribution by Scale of Operation
- 32.3.1. Cell Therapy Manufacturing Market in North America for Clinical Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.3.2. Cell Therapy Manufacturing Market in North America for Commercial Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.4. Cell Therapy Manufacturing Market in North America: Distribution by Type of Manufacturer
- 32.4.1. Cell Therapy Manufacturing Market in North America for Contract Manufacturing Organizations, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.4.2. Cell Therapy Manufacturing Market in North America for In-House Manufacturers, Historical Trends (since 2022) and Forecasted Estimates (till 2035)

33. CELL THERAPY MANUFACTURING MARKET OPPORTUNITY ANALYSIS: EUROPE

33.1. Cell Therapy Manufacturing Market in Europe: Distribution by Type of Cell therapy
- 33.1.1. Cell Therapy Manufacturing Market in Europe for CAR-T Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.1.2. Cell Therapy Manufacturing Market in Europe for Stem Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.1.3. Cell Therapy Manufacturing Market in Europe for TCR Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.1.4. Cell Therapy Manufacturing Market in Europe for TIL Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.1.5. Cell Therapy Manufacturing Market in Europe for Dendritic Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.1.6. Cell Therapy Manufacturing Market in Europe for Other Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.2. Cell Therapy Manufacturing Market in Europe: Distribution by Source of Cells
- 33.2.1. Cell Therapy Manufacturing Market in Europe for Autologous Cells, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.2.2. Cell Therapy Manufacturing Market in Europe for Allogeneic Cells, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.2.3. Cell Therapy Manufacturing Market in Europe for Other Cells, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.3. Cell Therapy Manufacturing Market in Europe: Distribution by Scale of Operation
- 33.3.1. Cell Therapy Manufacturing Market in Europe for Clinical Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.3.2. Cell Therapy Manufacturing Market in Europe for Commercial Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.4. Cell Therapy Manufacturing Market in Europe: Distribution by Type of Manufacturer
- 33.4.1. Cell Therapy Manufacturing Market in Europe for Contract Manufacturing Organizations, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.4.2. Cell Therapy Manufacturing Market in Europe for In-House Manufacturers, Historical Trends (since 2022) and Forecasted Estimates (till 2035)

34. CELL THERAPY MANUFACTURING MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC AND REST OF THE WORLD

34.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Type of Cell therapy
- 34.1.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for CAR-T Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.1.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Stem Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.1.3. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for TCR Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.1.4. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for TIL Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.1.5. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Dendritic Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.1.6. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Other Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Source of Cells
- 34.2.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Autologous Cells, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.2.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Allogeneic Cells, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.2.3. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Other Cells, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.3. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Scale of Operation
- 34.3.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Clinical Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.3.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Commercial Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.4. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Type of Manufacturer
- 34.4.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Contract Manufacturing Organizations, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.4.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for In-House Manufacturers, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
*Detailed information on Chapters 32-34 is available in the Excel Data Packs shared along with the report**

35. CONCLUDING REMARKS

36. EXECUTIVE INSIGHTS

36.1. Chapter Overview
36.2. Company A (Mid-sized Company, Australia)
- 36.2.1. Company Snapshot
- 36.2.2. Interview Transcript: Marketing Manager, Cell Therapy
36.3. Company B (UK)
- 36.3.1. Company Snapshot
- 36.3.2. Interview Transcript: Director
36.4. Company C (Small Company, Belgium)
- 36.4.1. Company Snapshot
- 36.4.2. Interview Transcript: Marketing Director
36.5. Company D (Large Company, Poland)
- 36.5.1. Company Snapshot
- 36.5.2. Interview Transcript: Management Board Vice-President
36.6. Company E (Small Company, US)
- 36.6.1. Company Snapshot
- 36.6.2. Interview Transcript: Senior Director of Sales Advanced Therapies; Vice President of Marketing
36.7. Company F (Mid-sized Company, Japan)
- 36.7.1. Company Snapshot
- 36.7.2. Interview Transcript: Business Administration Department Manager
36.8. Company G (Small Company, Netherlands)
- 36.8.1. Company Snapshot
- 36.8.2. Interview Transcript: Chief Business Officer
36.9. Company H (US)
- 36.9.1. Company Snapshot
- 36.9.2. Interview Transcript: Director of Finance and Facility Operations
36.10. Company I (Very Large Company, Japan)
- 36.10.1. Company Snapshot
- 36.10.2. Interview Transcript: Senior Director
36.11. Company J (Mid-sized Company, UK)
- 36.11.1. Company Snapshot
- 36.11.2. Interview Transcript: Chief Executive Officer
36.12. Company K (Large Company, US)
- 36.12.1. Company Snapshot
- 36.12.2. Interview Transcript: Former Chief Technical Officer
36.13. Company L (Small Company, Netherlands)
- 36.13.1. Company Snapshot
- 36.13.2. Interview Transcript: Former Chief Executive Officer,
36.14. Company M (Small Company, France)
- 36.14.1. Company Snapshot
- 36.14.2. Interview Transcript: Former General Manager
36.15. Company N (Large Company, China)
- 36.15.1. Company Snapshot
- 36.15.2. Interview Transcript: Chief Executive Officer
36.16. Company O (Small Company, Israel)
- 36.16.1. Company Snapshot
- 36.16.2. Interview Transcript: Executive Vice President Research and Development
36.17. Company P (Mid-sized Company, UK)
- 36.17.1. Company Snapshot
- 36.17.2. Interview Transcript: Former Business Development Manager
36.18. Company Q (US)
- 36.18.1. Company Snapshot
- 36.18.2. Interview Transcript: Professor and American Red Cross Chair in Transfusion Medicine
36.19. Company R (Small Company, Singapore)
- 36.19.1. Company Snapshot
- 36.19.2. Interview Transcript: Former Co-Founder and Chief Executive Officer
36.20. Company S (Mid-sized Company, Canada)
- 36.20.1. Company Snapshot
- 36.20.2. Interview Transcript: Former Manager, Business Development and Operations-cGMP Manufacturing Unit
36.21. Company T (Small Company, US)
- 36.21.1. Company Snapshot
- 36.21.2. Interview Transcript: Manager of Business Development
36.22. Company U (Mid-sized Company, France)
- 36.22.1. Company Snapshot
- 36.22.2. Interview Transcript: Former Department Leader, Cell Therapy Innovation and Development
36.23. Company V (Mid-sized Company, Australia)
- 36.23.1. Company Snapshot
- 36.23.2. Interview Transcript: Former Chief Executive Officer
36.24. Company W (Small Company, Netherlands)
- 36.24.1. Company Snapshot
- 36.24.2. Interview Transcript: Chief Executive Officer

37. APPENDIX I: TABULATED DATA

38. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

Product Code: RA100392

List of Tables

Table 6.1 Cell-based Therapies: Applications
Table 6.2 Differences between Cell Therapy and Biotechnological Products
Table 6.3 Cell-based Therapies: Commercialized Products
Table 6.4 Assessment of Cell Therapy Manufacturing Steps
Table 6.5 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 7.1 Industry Players: Information on Year of Establishment, Company Size, Location of Headquarters, Number of Manufacturing Facilities and Location of Manufacturing Facility
Table 7.2 Industry Players: Information on Type of Immune Cell Offered
Table 7.3 Industry Players: Information on Source of Cells and Scale of Operation
Table 7.4 Industry Players: Information on Type of Additional Service Offered
Table 8.1 Non-Industry Players: Information on Year of Establishment, Location of Headquarters, Number of Manufacturing Facilities and Location of Manufacturing Facility
Table 8.2 Non-Industry Players: Information on Type of Immune Cell Offered
Table 8.3 Non-Industry Players: Information on Source of Cell and Scale of Operation
Table 8.4 Non-Industry Players: Information on Type of Additional Service Offered
Table 9.1 Cell Therapy Manufacturing (Industry Players): Regulatory Authorities
Table 9.2 Cell Therapy Manufacturing (Non-Industry Players): Regulatory Authorities
Table 9.3 Summary of Guidelines for Early-Stage Manufacturing of Cell Therapies
Table 10.1 Cell Therapy Manufacturing: Roadmap for the US
Table 10.2 Cell Processing: Challenges and Strategies
Table 10.3 Cell Preservation, Distribution and Handling: Challenges and Strategies
Table 10.4 Process Monitoring and Quality Control: Challenges and Strategies
Table 10.5 Standardization and Regulatory Support: Challenges and Strategies
Table 10.6 Workforce Development: Challenges and Strategies
Table 10.7 Supply Chain and Logistics: Challenges and Strategies
Table 10.8 Cell Therapy Manufacturing: Roadmap for the Asia Pacific Economic Cooperation (APEC)
Table 11.1 Cell Therapy Manufacturing: List of Automated and Closed Cell Therapy Processing Systems
Table 12.1 Cell Therapy Manufacturing Industry Players: List of Companies Profiled
Table 12.2 Advanced Therapies: Company Snapshot
Table 12.3 Advanced Therapies: Information on Manufacturing Facilities and Capabilities
Table 12.4 Advanced Therapies: Recent Developments and Future Outlook
Table 12.5 AGC Biologics: Company Snapshot
Table 12.6 AGC Biologics: Information on Manufacturing Facilities and Capabilities
Table 12.7 AGC Biologics: Recent Developments and Future Outlook
Table 12.8 Catalent: Company Snapshot
Table 12.9 Catalent: Information on Manufacturing Facilities and Capabilities
Table 12.10 Catalent: Recent Developments and Future Outlook
Table 12.11 Charles River Laboratories: Company Snapshot
Table 12.12 Charles River Laboratories: Information on Manufacturing Facilities and Capabilities
Table 12.13 Charles River Laboratories: Recent Developments and Future Outlook
Table 12.14 ImmunityBio: Company Snapshot
Table 12.15 ImmunityBio: Information on Manufacturing Facilities and Capabilities
Table 12.16 ImmunityBio: Recent Developments and Future Outlook
Table 12.17 Merck Millipore: Company Snapshot
Table 12.18 Merck Millipore: Information on Manufacturing Facilities and Capabilities
Table 12.19 Merck Millipore: Recent Developments and Future Outlook
Table 12.20 Minaris Advanced Therapies: Company Snapshot
Table 12.21 Minaris Advanced Therapies: Information on Manufacturing Facilities and Capabilities
Table 12.22 Minaris Advanced Therapies: Recent Developments and Future Outlook
Table 12.23 Resilience: Company Snapshot
Table 12.24 Resilience: Information on Manufacturing Facilities and Capabilities
Table 12.25 Resilience: Recent Developments and Future Outlook
Table 12.26 SK pharmteco (Subsidiary of SK Inc.): Company Snapshot
Table 12.27 SK pharmteco (Subsidiary of SK Inc.): Information on Manufacturing Facilities and Capabilities
Table 12.28 SK pharmteco (Subsidiary of SK Inc.): Recent Developments and Future Outlook
Table 12.29 Thermo Fisher Scientific: Company Snapshot
Table 12.30 Thermo Fisher Scientific: Information on Manufacturing Facilities and Capabilities
Table 12.31 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 13.1 Cell Therapy Manufacturing (Non-Industry Players): List of Organizations Profiled
Table 13.2 City of Hope: Overview
Table 13.3 City of Hope: Service Portfolio
Table 13.4 Clinical Cell and Vaccine Production Facility (CVPF): Overview
Table 13.5 Clinical Cell and Vaccine Production Facility (CVPF): Service Portfolio
Table 13.6 Fraunhofer Institute for Cell Therapy and Immunology: Overview
Table 13.7 Fraunhofer Institute for Cell Therapy and Immunology: Service Portfolio
Table 13.8 Newcastle Advanced Therapies: Overview
Table 13.9 Newcastle Advanced Therapies: Service Portfolio
Table 13.10 NHS Blood and Transplant: Overview
Table 13.11 NHS Blood and Transplant: Service Portfolio
Table 13.12 Rayne Cell Therapy Suite (King's College London): Overview
Table 13.13 Rayne Cell Therapy Suite (King's College London): Service Portfolio
Table 13.14 Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility: Overview
Table 13.15 Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility: Service Portfolio
Table 14.1 Cell Therapy Manufacturing: List of Non-Profit Organizations
Table 14.2 CellCAN: Overview
Table 14.3 Cell Therapy Manufacturing Cooperative Research Center: Overview
Table 14.4 National Cell Manufacturing Consortium: Overview
Table 14.5 California's Institute of Regenerative Medicine: Overview
Table 16.1 Cell Therapy Manufacturing: List of Partnerships and Collaborations
Table 16.2 Partnerships and Collaborations: Information on Type of Immune Cell Offered and Scale of Operation
Table 16.3 Partnerships and Collaborations: Information on Location of Headquarters (Country and Region) and Type of Agreement (Country and Region)
Table 17.1 Cell Therapy Manufacturing: List of Expansions
Table 17.2 Cell Therapy Manufacturing: Type of Immune Cell Offered and Scale of Operation
Table 18.1 List of Top 10 Big Pharma Players
Table 18.2 Big Pharma Players: List of Cell Therapy Manufacturing Focused Initiatives, Since 2021
Table 18.3 Big Pharma Initiatives: Information on Type of Immune Cell Offered and Scale of Operation
Table 19.1 Average Installed Cell Therapy Manufacturing Capacity (Number of Cleanrooms): Sample Data Set for Industry Players
Table 19.2 Average Installed Cell Therapy Manufacturing Capacity (Cleanroom Area): Sample Data Set for Industry Players
Table 19.3 Global Installed capacity of industry players for cell therapy manufacturing (Number of Cleanrooms): Distribution by Company Size
Table 19.4 Global Installed capacity of industry players for cell therapy manufacturing (Cleanroom Area): Distribution by Company Size
Table 19.5 Median Installed Cell Therapy Manufacturing Capacity (Number of Cleanrooms): Data Set for Non-Industry Players
Table 19.6 Median Installed Cell Therapy Manufacturing Capacity (Cleanroom Area): Dat Set for Non-Industry Players
Table 21.1 Costs Associated with Manufacturing Stem Cell Therapies
Table 21.2 Pricing Model: Price of Marketed Drugs (Antibody Drug Conjugates and Monoclonal Antibodies)
Table 21.3 T-cell Immunotherapies: Expert Opinions on Pricing
Table 21.4 CAR-T Cell Therapies: Reimbursement Landscape
Table 23.1 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20 (USD Million)
Table 23.2 Total Cost of Ownership: Sample Dataset
Table 25.1 Survey Insights: Overview of Respondents
Table 25.2 Survey Insights: Designations and Seniority Levels
Table 25.3 Survey Insights: Type of Cell Therapy
Table 25.4 Survey Insights: Scale of Operation
Table 25.5 Survey Insights: Source of Cells
Table 25.6 Survey Insights: Cell Culture System
Table 25.7 Survey Insights: Availability of Fill / Finish Services
Table 37.1 Industry Players: Distribution by Year of Establishment
Table 37.2 Industry Players: Distribution by Company Size
Table 37.3 Industry Players: Distribution by Location of Headquarters (Region)
Table 37.4 Industry Players: Distribution by Location of Headquarters (Country)
Table 37.5 Industry Players: Distribution by Company Size and Location of Headquarters (Region)
Table 37.6 Industry Players: Distribution by Location of Manufacturing Facility (Region)
Table 37.7 Industry Players: Distribution by Location of Manufacturing Facility (Country)
Table 37.8 Industry Players: Distribution by Type of Immune Cell Offered
Table 37.9 Industry Players: Distribution by Source of Cells
Table 37.10 Industry Players: Distribution by Scale of Operation
Table 37.11 Industry Players: Distribution by Type of Additional Service Offered
Table 37.12 Non-Industry Players: Distribution by Year of Establishment
Table 37.13 Non-Industry Players: Distribution by Location of Headquarters (Region)
Table 37.14 Non-Industry Players: Distribution by Location of Headquarters (Country)
Table 37.15 Non-Industry Players: Distribution by Location of Manufacturing Facility (Region)
Table 37.16 Non-Industry Players: Distribution by Location of Manufacturing Facility (Country)
Table 37.17 Non-Industry Players: Distribution by Type of Immune Cell Offered
Table 37.18 Non-Industry Players: Distribution by Source of Cell
Table 37.19 Non-Industry Players: Distribution by Scale of Operation
Table 37.20 Non-Industry Players: Distribution by Type of Additional Service Offered
Table 37.21 Cell Therapy Manufacturing (Industry Players): Distribution by Regulatory Authorities / Certifications
Table 37.22 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Regulatory Authorities / Certifications
Table 37.23 WuXi AppTec (parent company of Advanced Therapies): Annual Revenues, FY 2022 - H1 FY 2025 (RMB Billion)
Table 37.24 AGC Biologics: Annual Revenues, FY 2022 - H1 FY 2025 (JPY Billion)
Table 37.25 Catalent: Annual Revenues, FY 2021 - Q1 FY 2025 (USD Billion)
Table 37.26 Charles River Laboratories: Annual Revenues, FY 2022- H1 FY 2025 (USD Billion)
Table 37.27 ImmunityBio: Annual Revenues, FY 2023- H1 FY 2025 (USD Million)
Table 37.28 Merck KGaA (Parent company of Merck Millipore): Annual Revenues, FY 2022- H1 FY 2025 (EUR Billion)
Table 37.29 Thermo Fisher Scientific: Annual Revenues, FY 2022 - 9M FY 2025 (JPY Billion)
Table 37.30 Evotec: Annual Revenues, FY 2022 - H1 FY 2025 (EUR Million)
Table 37.31 Lonza: Annual Revenues, FY 2022 - H1 FY 2025 (CHF Billion)
Table 37.32 Sartorius: Annual Revenues, FY 2022 - 9M FY 2025 (EUR Billion)
Table 37.33 Astellas Pharma: Annual Revenues, FY 2022 - Q1 FY 2025 (YEN Billion)
Table 37.34 Pharmaron: Annual Revenues, FY 2022 - H1 FY 2025 (RMB Billion)
Table 37.35 Takara Bio: Annual Revenues, FY 2023 - Q1 FY 2026 (YEN Billion)
Table 37.36 Clinical Trial Analysis: Distribution by Trial Registration Year, Since 2021
Table 37.37 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Since 2021
Table 37.38 Clinical Trial Analysis: Distribution by Trial Status
Table 37.39 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 37.40 Clinical Trial Analysis: Distribution by Trial Phase
Table 37.41 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 37.42 Clinical Trial Analysis: Distribution by Patient Gender
Table 37.43 Clinical Trial Analysis: Distribution by Type of Allocation
Table 37.44 Clinical Trial Analysis: Distribution by Type of Intervention Model
Table 37.45 Clinical Trial Analysis: Distribution by Type of Masking
Table 37.46 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 37.47 Most Active Industry Players: Distribution by Number of Registered Trials
Table 37.48 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 37.49 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 37.50 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Table 37.51 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
Table 37.52 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2021
Table 37.53 Partnerships and Collaborations: Distribution by Type of Partnership
Table 37.54 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 37.55 Partnerships and Collaborations: Distribution by Type of Immune Cell
Table 37.56 Partnerships and Collaborations: Distribution by Scale of Operation
Table 37.57 Most Active Players: Distribution by Number of Partnerships
Table 37.58 Partnerships and Collaborations: Local and International Agreements
Table 37.59 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 37.60 Recent Expansions: Cumulative Year-wise Trend, Since 2021
Table 37.61 Recent Expansions: Distribution by Type of Expansion
Table 37.62 Recent Expansions: Distribution by Year and Type of Expansion
Table 37.63 Recent Expansions: Distribution by Location of Expanded Facility (Region)
Table 37.64 Recent Expansions: Distribution by Location of Expanded Facility (Country)
Table 37.65 Recent Expansions: Distribution by Type of Expansion and Location of Headquarters (Country)
Table 37.66 Recent Expansions: Distribution by Type of Immune Cell
Table 37.67 Recent Expansions: Distribution by Type of Expansion and Type of Immune Cell
Table 37.68 Recent Expansions: Distribution by Scale of Operation
Table 37.69 Most Active Players: Distribution by Number of Expansions
Table 37.70 Most Active Players: Distribution by Area of Expansion (in sq ft)
Table 37.71 Big Pharma Initiatives: Distribution by Year of Initiative
Table 37.72 Big Pharma Initiatives: Distribution by Type of Initiative
Table 37.73 Big Pharma Initiatives: Distribution by Year and Type of Initiative
Table 37.74 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Initiatives
Table 37.75 Big Pharma Initiatives: Distribution by Type of Partnership
Table 37.76 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Partnerships
Table 37.77 Big Pharma Initiatives: Distribution by Type of Facility Expansion
Table 37.78 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Facility Expansion
Table 37.79 Big Pharma Initiatives: Distribution of Big Pharma Players by Region of Facility Expansion
Table 37.80 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Mergers and Acquisitions
Table 37.81 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Funding and Investment
Table 37.82 Big Pharma Initiatives: Distribution by Type of Immune Cell
Table 37.83 Big Pharma Initiatives: Distribution by Scale of Operation
Table 37.84 Big Pharma Initiatives: Distribution of Big Pharma Players by Scale of Operation
Table 37.85 Big Pharma Initiatives Summary
Table 37.86 Global Installed Capacity of Industry Players for Cell Therapy Manufacturing: Distribution by Range of Installed Capacity
Table 37.87 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Company Size
Table 37.88 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Scale of Operation
Table 37.89 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Location of Manufacturing Facility
Table 37.90 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Company Size and Location of Manufacturing Facility
Table 37.91 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Scale of Operation and Location of Manufacturing Facility
Table 37.92 Global Installed Capacity of Industry Players for Cell Therapy Manufacturing (Cleanroom Area, sq. ft.): Distribution by Company Size and Range of Installed Capacity
Table 37.93 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Company Size
Table 37.94 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Scale of Operation
Table 37.95 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Location of Manufacturing Facility
Table 37.96 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Company Size and Location of Manufacturing Facility
Table 37.97 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Scale of Operation and Location of Manufacturing Facility
Table 37.98 Global Installed Capacity of Non-Industry Players for Cell Therapy Manufacturing: Distribution by Range of Number of Cleanrooms
Table 37.99 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Scale of Operation
Table 37.100 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Location of Manufacturing Facility
Table 37.101 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Range of Installed Capacity
Table 37.102 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Scale of Operation
Table 37.103 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Location of Manufacturing Facility
Table 37.104 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (Number of Patients)
Table 37.105 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Cells in Billion)
Table 37.106 Global Clinical Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Table 37.107 Clinical Demand for Cell Therapy Manufacturing: Distribution by Type of Cell Therapy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Table 37.108 Clinical Demand for Cell Therapy Manufacturing: Distribution by Geography, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Table 37.109 Global Commercial Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Table 37.110 Commercial Demand for Cell Therapy Manufacturing: Distribution by Type of Cell Therapy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Table 37.111 Commercial Demand for Cell Therapy Manufacturing: Distribution by Geography, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Table 37.112 Global Cell Therapy Manufacturing Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.113 Global Cell Therapy Manufacturing Market, Forecasted Estimates (till 2035), Conservative Scenario (USD Million)
Table 37.114 Global Cell Therapy Manufacturing Market, Forecasted Estimates (till 2035), Optimistic Scenario (USD Million)
Table 37.115 Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy
Table 37.116 Cell Therapy Manufacturing Market for CAR-T Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.117 Cell Therapy Manufacturing Market for Stem Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.118 Cell Therapy Manufacturing Market for TCR Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.119 Cell Therapy Manufacturing Market for TIL Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.120 Cell Therapy Manufacturing Market for Dendritic Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.121 Cell Therapy Manufacturing Market for Other Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.122 Cell Therapy Manufacturing Market: Distribution by Source of Cells
Table 37.123 Cell Therapy Manufacturing Market for Autologous Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.124 Cell Therapy Manufacturing Market for Allogeneic Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.125 Cell Therapy Manufacturing Market for Other Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.126 Cell Therapy Manufacturing Market: Distribution by Scale of Operation
Table 37.127 Cell Therapy Manufacturing Market for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.128 Cell Therapy Manufacturing Market for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.129 Cell Therapy Manufacturing Market: Distribution by Type of Manufacturer
Table 37.130 Cell Therapy Manufacturing Market for Contract Manufacturing Organizations, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.131 Cell Therapy Manufacturing Market for In-House Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.132 Cell Therapy Manufacturing Market: Distribution by Geography
Table 37.133 Clinical Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.134 Clinical Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.135 Clinical Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.136 Clinical Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.137 Clinical Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.138 Clinical Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.139 Clinical Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.140 Clinical Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.141 Clinical Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.142 Clinical Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.143 Clinical Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.144 Clinical Cell Therapy Manufacturing Market in Singapore, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.145 Clinical Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.146 Clinical Cell Therapy Manufacturing Market in Israel, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.147 Clinical Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.148 Clinical Cell Therapy Manufacturing Market in Taiwan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.149 Clinical Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.150 Clinical Cell Therapy Manufacturing Market in Argentina, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.151 Clinical Cell Therapy Manufacturing Market in South Africa, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.152 Commercial Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.153 Commercial Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.154 Commercial Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.155 Commercial Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.156 Commercial Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.157 Commercial Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.158 Commercial Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.159 Commercial Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.160 Commercial Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.161 Commercial Cell Therapy Manufacturing Market in Rest of Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.162 Commercial Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.163 Commercial Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.164 Commercial Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.165 Commercial Cell Therapy Manufacturing Market in Australia, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.166 Commercial Cell Therapy Manufacturing Market in India, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.167 Commercial Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 37.168 Commercial Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (USD Million)

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends (I / II)
Figure 5.3 Executive Summary: Market Trends (II / II)
Figure 5.4 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Classification of Advanced Therapy Medicinal Products (ATMPs)
Figure 6.2 Decentralized Manufacturing: Process Model
Figure 6.3 Cell Therapy Manufacturing: Type of Manufacturer
Figure 6.4 Cell Therapies: Challenges and Drivers
Figure 6.5 Cell Therapies: Potency as a Critical Quality Attribute
Figure 6.6 Cell Therapy Manufacturing: Supply Chain Model
Figure 7.1 Industry Players: Distribution by Year of Establishment
Figure 7.2 Industry Players: Distribution by Company Size
Figure 7.3 Industry Players: Distribution by Location of Headquarters (Region)
Figure 7.4 Industry Players: Distribution by Location of Headquarters (Country)
Figure 7.5 Industry Players: Distribution by Company Size and Location of Headquarters (Region)
Figure 7.6 Industry Players: Distribution by Location of Manufacturing Facility (Region)
Figure 7.7 Industry Players: Distribution by Location of Manufacturing Facility (Country)
Figure 7.8 Industry Players: Distribution by Type of Immune Cell Offered
Figure 7.9 Industry Players: Distribution by Source of Cells
Figure 7.10 Industry Players: Distribution by Scale of Operation
Figure 7.11 Industry Players: Distribution by Type of Additional Service Offered
Figure 8.1 Non-Industry Players: Distribution by Year of Establishment
Figure 8.2 Non-Industry Players: Distribution by Location of Headquarters (Region)
Figure 8.3 Non-Industry Players: Distribution by Location of Headquarters (Country)
Figure 8.4 Non-Industry Players: Distribution by Location of Manufacturing Facility (Region)
Figure 8.5 Non-Industry Players: Distribution by Location of Manufacturing Facility (Country)
Figure 8.6 Non-Industry Players: Distribution by Type of Immune Cell Offered
Figure 8.7 Non-Industry Players: Distribution by Source of Cell
Figure 8.8 Non-Industry Players: Distribution by Scale of Operation
Figure 8.9 Non-Industry Players: Distribution by Type of Additional Service Offered
Figure 9.1 Cell Therapy Manufacturing (Industry Players): Distribution by Regulatory Authorities / Certifications
Figure 9.2 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Regulatory Authorities / Certifications
Figure 11.1 Key Considerations for Automating Cell Therapy Manufacturing Process
Figure 11.2 Requirements to Implement Closed Systems in Cell Therapy Manufacturing Processes
Figure 11.3 Functions of Automated and Closed Systems at Each Step of the Cell Therapy Manufacturing Process
Figure 11.4 Advantages and Disadvantages of Single-Use System
Figure 11.5 Growth Drivers and Roadblocks to the Automated and Closed Systems
Figure 11.6 Cell Therapy Manufacturing: Roadmap for Developing an Automated Device
Figure 11.7 Cell Therapy Manufacturing: Comparison Between Manual and Automated Processes
Figure 11.8 Cell Therapy Manufacturing: Comparative Analysis of Manual and Automated Processes Based on Affiliated Costs
Figure 12.1 WuXi AppTec (parent company of Advanced Therapies): Annual Revenues, FY 2022 - H1 FY 2025 (RMB Billion)
Figure 12.2 AGC Biologics: Annual Revenues, FY 2022 - H1 FY 2025 (JPY Billion)
Figure 12.3 Catalent: Annual Revenues, FY 2021 - Q1 FY 2025 (USD Billion)
Figure 12.4 Charles River Laboratories: Annual Revenues, FY 2022- H1 FY 2025 (USD Billion)
Figure 12.5 ImmunityBio: Annual Revenues, FY 2023- H1 FY 2025 (USD Million)
Figure 12.6 Merck KGaA (Parent company of Merck Millipore): Annual Revenues, FY 2022- H1 FY 2025 (EUR Billion)
Figure 12.7 Thermo Fisher Scientific: Annual Revenues, FY 2022 - 9M FY 2025 (JPY Billion)
Figure 12.8 Evotec: Annual Revenues, FY 2022 - H1 FY 2025 (EUR Million)
Figure 12.9 Lonza: Annual Revenues, FY 2022 - H1 FY 2025 (CHF Billion)
Figure 12.10 Sartorius: Annual Revenues, FY 2022 - 9M FY 2025 (EUR Billion)
Figure 12.11 Astellas Pharma: Annual Revenues, FY 2022 - Q1 FY 2025 (YEN Billion)
Figure 12.12 Pharmaron: Annual Revenues, FY 2022 - H1 FY 2025 (RMB Billion)
Figure 12.13 Takara Bio: Annual Revenues, FY 2023 - Q1 FY 2026 (YEN Billion)
Figure 13.1 City of Hope: Type of Additional Service Offered
Figure 13.2 Clinical Cell and Vaccine Production Facility (CVPF): Type of Additional Service Offered
Figure 13.3 Fraunhofer Institute for Cell Therapy and Immunology: Type of Additional Service Offered
Figure 13.4 Newcastle Advanced Therapies: Type of Additional Service Offered
Figure 13.5 NHS Blood and Transplant: Type of Additional Service Offered
Figure 13.6 Rayne Cell Therapy Suite (King's College London): Type of Additional Service Offered
Figure 13.7 Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility: Type of Additional Service Offered
Figure 15.1 Clinical Trial Analysis: Distribution by Trial Registration Year, Since 2021
Figure 15.2 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Since 2021
Figure 15.3 Clinical Trial Analysis: Distribution by Trial Status
Figure 15.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 15.5 Clinical Trial Analysis: Distribution by Trial Phase
Figure 15.6 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 15.7 Clinical Trial Analysis: Distribution by Patient Gender
Figure 15.8 Clinical Trial Analysis: Distribution by Type of Allocation
Figure 15.9 Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 15.10 Clinical Trial Analysis: Distribution by Type of Masking
Figure 15.11 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 15.12 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 15.13 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 15.14 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 15.15 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Figure 15.16 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
Figure 16.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2021
Figure 16.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 16.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 16.4 Partnerships and Collaborations: Distribution by Type of Immune Cell
Figure 16.5 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 16.6 Most Active Players: Distribution by Number of Partnerships
Figure 16.7 Partnerships and Collaborations: Local and International Agreements
Figure 16.8 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 17.1 Recent Expansions: Cumulative Year-wise Trend, Since 2021
Figure 17.2 Recent Expansions: Distribution by Type of Expansion
Figure 17.3 Recent Expansions: Distribution by Year and Type of Expansion
Figure 17.4 Recent Expansions: Distribution by Location of Expanded Facility (Region)
Figure 17.5 Recent Expansions: Distribution by Location of Expanded Facility (Country)
Figure 17.6 Recent Expansions: Distribution by Type of Expansion and Location of Headquarters (Country)
Figure 17.7 Recent Expansions: Distribution by Type of Immune Cell
Figure 17.8 Recent Expansions: Distribution by Type of Expansion and Type of Immune Cell
Figure 17.9 Recent Expansions: Distribution by Scale of Operation
Figure 17.10 Most Active Players: Distribution by Number of Expansions
Figure 17.11 Most Active Players: Distribution by Area of Expansion (in sq ft)
Figure 18.1 Big Pharma Initiatives: Distribution by Year of Initiative
Figure 18.2 Big Pharma Initiatives: Distribution by Type of Initiative
Figure 18.3 Big Pharma Initiatives: Distribution by Year and Type of Initiative
Figure 18.4 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Initiatives
Figure 18.5 Big Pharma Initiatives: Distribution by Type of Partnership
Figure 18.6 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Partnerships
Figure 18.7 Big Pharma Initiatives: Distribution by Type of Facility Expansion
Figure 18.8 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Facility Expansion
Figure 18.9 Big Pharma Initiatives: Distribution of Big Pharma Players by Region of Facility Expansion
Figure 18.10 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Mergers and Acquisitions
Figure 18.11 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Funding and Investment
Figure 18.12 Big Pharma Initiatives: Distribution by Type of Immune Cell
Figure 18.13 Big Pharma Initiatives: Distribution by Scale of Operation
Figure 18.14 Big Pharma Initiatives: Distribution of Big Pharma Players by Scale of Operation
Figure 18.15 Big Pharma Initiatives Summary
Figure 19.1 Global Installed Capacity of Industry Players for Cell Therapy Manufacturing: Distribution by Range of Installed Capacity
Figure 19.2 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Company Size
Figure 19.3 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Scale of Operation
Figure 19.4 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Location of Manufacturing Facility
Figure 19.5 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Company Size and Location of Manufacturing Facility
Figure 19.6 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Scale of Operation and Location of Manufacturing Facility
Figure 19.7 Global Installed Capacity of Industry Players for Cell Therapy Manufacturing (Cleanroom Area, sq. ft.): Distribution by Company Size and Range of Installed Capacity
Figure 19.8 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Company Size
Figure 19.9 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Scale of Operation
Figure 19.10 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Location of Manufacturing Facility
Figure 19.11 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Company Size and Location of Manufacturing Facility
Figure 19.12 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Scale of Operation and Location of Manufacturing Facility
Figure 19.13 Global Installed Capacity of Non-Industry Players for Cell Therapy Manufacturing: Distribution by Range of Number of Cleanrooms
Figure 19.14 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Scale of Operation
Figure 19.15 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Location of Manufacturing Facility
Figure 19.16 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Range of Installed Capacity
Figure 19.17 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Scale of Operation
Figure 19.18 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Location of Manufacturing Facility
Figure 20.1 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (Number of Patients)
Figure 20.2 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Cells in Billion)
Figure 20.3 Global Clinical Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Figure 20.4 Clinical Demand for Cell Therapy Manufacturing: Distribution by Type of Cell Therapy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Figure 20.5 Clinical Demand for Cell Therapy Manufacturing: Distribution by Geography, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Figure 20.6 Global Commercial Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Figure 20.7 Commercial Demand for Cell Therapy Manufacturing: Distribution by Type of Cell Therapy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Figure 20.8 Commercial Demand for Cell Therapy Manufacturing: Distribution by Geography, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Figure 21.1 Targeted Therapies: Pricing Model Based on Patient Segment
Figure 22.1 Make versus Buy Decision Making Framework
Figure 22.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 23.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 23.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 23.3 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20 (USD Million)
Figure 23.4 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Distribution by CAPEX and OPEX, Y0 and Y20 (USD Million)
Figure 23.5 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Figure 23.6 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Figure 24.1 Cell Therapy Manufacturing: SWOT Analysis
Figure 24.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 25.1 Survey Insights: Distribution of Respondents by Type of Organization
Figure 25.2 Survey Insights: Distribution of Respondents by Location of Manufacturing Facility
Figure 25.3 Survey Insights: Distribution by Designation and Seniority of Respondents
Figure 25.4 Survey Insights: Distribution by Type of Cell Therapy
Figure 25.5 Survey Insights: Distribution by Scale of Operation
Figure 25.6 Survey Insights: Distribution by Source of Cells
Figure 25.7 Survey Insights: Distribution by Cell Culture System
Figure 26.1 Global Cell Therapy Manufacturing Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.2 Global Cell Therapy Manufacturing Market, Forecasted Estimates (till 2035), Conservative Scenario (USD Million)
Figure 26.3 Global Cell Therapy Manufacturing Market, Forecasted Estimates (till 2035), Optimistic Scenario (USD Million)
Figure 27.1 Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy
Figure 27.2 Cell Therapy Manufacturing Market for CAR-T Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 27.3 Cell Therapy Manufacturing Market for Stem Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 27.4 Cell Therapy Manufacturing Market for TCR Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 27.5 Cell Therapy Manufacturing Market for TIL Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 27.6 Cell Therapy Manufacturing Market for Dendritic Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 27.7 Cell Therapy Manufacturing Market for Other Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 28.1 Cell Therapy Manufacturing Market: Distribution by Source of Cells
Figure 28.2 Cell Therapy Manufacturing Market for Autologous Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 28.3 Cell Therapy Manufacturing Market for Allogeneic Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 28.4 Cell Therapy Manufacturing Market for Other Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 29.1 Cell Therapy Manufacturing Market: Distribution by Scale of Operation
Figure 29.2 Cell Therapy Manufacturing Market for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 29.3 Cell Therapy Manufacturing Market for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 30.1 Cell Therapy Manufacturing Market: Distribution by Type of Manufacturer
Figure 30.2 Cell Therapy Manufacturing Market for Contract Manufacturing Organizations, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 30.3 Cell Therapy Manufacturing Market for In-House Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.1 Cell Therapy Manufacturing Market: Distribution by Geography
Figure 31.2 Clinical Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.3 Clinical Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.4 Clinical Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.5 Clinical Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.6 Clinical Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.7 Clinical Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.8 Clinical Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.9 Clinical Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.10 Clinical Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.11 Clinical Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.12 Clinical Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.13 Clinical Cell Therapy Manufacturing Market in Singapore, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.14 Clinical Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.15 Clinical Cell Therapy Manufacturing Market in Israel, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.16 Clinical Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.17 Clinical Cell Therapy Manufacturing Market in Taiwan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.18 Clinical Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.19 Clinical Cell Therapy Manufacturing Market in Argentina, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.20 Clinical Cell Therapy Manufacturing Market in South Africa, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.21 Commercial Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.22 Commercial Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.23 Commercial Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.24 Commercial Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.25 Commercial Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.26 Commercial Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.27 Commercial Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.28 Commercial Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.29 Commercial Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.30 Commercial Cell Therapy Manufacturing Market in Rest of Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.31 Commercial Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.32 Commercial Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.33 Commercial Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.34 Commercial Cell Therapy Manufacturing Market in Australia, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.35 Commercial Cell Therapy Manufacturing Market in India, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.36 Commercial Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.37 Commercial Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (USD Million)
Figure 35.1 Conclusion: Market Landscape (Industry Players)
Figure 35.2 Conclusion: Market Landscape (Non-Industry Players)
Figure 35.3 Conclusion: Clinical Trial Analysis
Figure 35.4 Conclusion: Partnerships and Collaborations
Figure 35.5 Conclusion: Recent Expansions
Figure 35.6 Conclusion: Big Pharma Initiatives
Figure 35.7 Conclusion: Capacity Analysis
Figure 35.8 Conclusion: Demand Analysis
Figure 35.9 Conclusion: Total Cost of Ownership
Figure 35.10 Conclusion: Market Sizing and Opportunity Analysis

Cell Therapy Manufacturing Market (7th Edition): Trends and Forecast Till 2035 - Distribution by Type of Cell Therapy, Source of Cells, Scale of Operation, Type of Manufacturer, and Geography

Description

Table of Contents

List of Tables

Cell Therapy Manufacturing Market: Overview

Primary Research Overview

Example Players in Cell Therapy Manufacturing Market

TABLE OF CONTENTS

1. PREFACE

2. RESEARCH METHODOLOGY

3. MARKET DYNAMICS

4. MACRO-ECONOMIC INDICATORS

5. EXECUTIVE SUMMARY

6. INTRODUCTION

7. CELL THERAPY MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE

8. CELL THERAPY MANUFACTURERS (NON-INDUSTRY PLAYERS): MARKET LANDSCAPE

9. REGULATORY LANDSCAPE

10. CASE STUDY: ROADMAPS FOR OVERCOMING CHALLENGES RELATED TO CELL THERAPY MANUFACTURING

11. CASE STUDY: AUTOMATION TECHNOLOGIES FOR CELL THERAPY MANUFACTURING

12. COMPANY PROFILES: INDUSTRY PLAYERS

13. COMPANY PROFILES: NON-INDUSTRY PLAYERS

14. NON-PROFIT ORGANIZATIONS IN CELL THERAPY MANUFACTURING

15. CLINICAL TRIAL ANALYSIS

16. PARTNERSHIPS AND COLLABORATIONS

17. RECENT EXPANSIONS

18. BIG PHARMA INITIATIVES

19. CAPACITY ANALYSIS

20. DEMAND ANALYSIS

21. COST PRICE ANALYSIS

22. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

23. TOTAL COST OF OWNERSHIP FOR CELL THERAPY MANUFACTURING ORGANIZATIONS

24. SWOT ANALYSIS

25. SURVEY ANALYSIS

26. GLOBAL CELL THERAPY MANUFACTURING MARKET

27. CELL THERAPY MANUFACTURING MARKET, BY TYPE OF CELL THERAPY

28. CELL THERAPY MANUFACTURING MARKET, BY SOURCE OF CELLS

29. CELL THERAPY MANUFACTURING MARKET, BY SCALE OF OPERATION

30. CELL THERAPY MANUFACTURING MARKET, BY TYPE OF MANUFACTURER

31. CELL THERAPY MANUFACTURING MARKET, BY GEOGRAPHY

32. CELL THERAPY MANUFACTURING MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

33. CELL THERAPY MANUFACTURING MARKET OPPORTUNITY ANALYSIS: EUROPE

34. CELL THERAPY MANUFACTURING MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC AND REST OF THE WORLD

35. CONCLUDING REMARKS

36. EXECUTIVE INSIGHTS

37. APPENDIX I: TABULATED DATA

38. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

List of Figures